WO1999048537A1 - Use of scatter factor to enhance angiogenesis - Google Patents
Use of scatter factor to enhance angiogenesis Download PDFInfo
- Publication number
- WO1999048537A1 WO1999048537A1 PCT/US1999/006452 US9906452W WO9948537A1 WO 1999048537 A1 WO1999048537 A1 WO 1999048537A1 US 9906452 W US9906452 W US 9906452W WO 9948537 A1 WO9948537 A1 WO 9948537A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- scatter factor
- tissue
- ischemia
- nucleic acid
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- This invention relates to a method of enhancing wound healing and to a method of enhancing organ transplantation comprising the administration of scatter factor to promote angiogenesis .
- Scatter factor has previously been described as a cytokine which is secreted by fibroblasts (see Stoker et al., J. Cell Sci . , Vol. 77, pp. 209-223 (1985) and Stoker et al., Nature (London), Vol. 327, pp. 238-242 (1987)) and by vascular smooth muscle cells (see Rosen et al . , In Vi tro Cell Dev. Biol . , Vol. 25, pp. 163-173 (1989)). Scatter factor has been shown to disperse cohesive epithelial colonies and stimulate cell motility.
- HGF hepatocyte growth factor
- HGF Scatter factor
- angiogenesis refers to the formation of blood vessels. Specifically, angiogenesis is a multistep process in which endothelial cells focally degrade and invade through their own - 3 - basement membrane, migrate through interstitial stroma toward an angiogenic stimulus, proliferate proximal to the migrating tip, organize into blood vessels, and reattach to newly synthesized basement membrane (see Folkman et al . , Adv. Cancer Res . , Vol. 43, pp. 175-203 (1985)). These processes are controlled by soluble factors and by the extracellular matrix (see Ingber et al . , Cell , Vol. 58, pp. 803-805 (1985) ) .
- proteases such as plasminogen activators (the endothelial secretion of which is induced by scatter factor) are required during the early stages of angiogenesis, and since endothelial cell migration, proliferation and capillary tube formation occur during angiogenesis, the inventors hypothesized that scatter factor might enhance angiogenic activity in vivo . In addition, it is desirable to enhance angiogenic activity so that wound healing and organ transplantation can be enhanced.
- Scatter factor protein may be administered to a tissue or subject topically or by intravenous, intramuscular, intradermal, subcutaneous or intraperitoneal injection. Scatter factor protein is administered in amounts sufficient to promote angiogenesis in a subject, which is in the amount of about .1-1000 ng/kg body weight .
- Scatter factor protein may be administered as the wild type scatter factor protein, or analogues thereof, and may be produced synthetically or recombinantly, or may be isolated from native cells.
- “analogue” means functional variants of the wild type protein, and includes scatter factor protein isolated from mammalian sources other than human, such as mouse, as well as functional variants thereof.
- a nucleic acid sequence encoding scatter factor administered to a mammal may be genomic DNA or cDNA.
- the nucleic acid sequence may be administered using a number of procedures known to one skilled in the art, such as electroporation, DEAE Dextran, monocationic liposome fusion, polycationic liposome fusion, protoplast fusion, DNA coated microprojectile bombardment, by creation of an in vivo electrical field, injection with recombinant replication-defective viruses, homologous recombination, and naked DNA transfer. It is to be appreciated by one skilled in the art that any of the above methods of DNA transfer may be combined.
- a nucleic acid encoding scatter factor may also be administered to a mammal using gene therapy, i.e.
- a cell such as a stem cell or a tumor cell which expresses scatter factor introduced therein through viral transduction, homologous recombination, or transfection is also provided by the present invention. This cell may then be administered to a subject to promote angiogenesis.
- Expression of the nucleic acid sequence encoding scatter factor may be controlled and affected by the particular vector into which the nucleic acid sequence has been introduced.
- Some eukaryotic vectors have been engineered so that they are capable of expressing inserted nucleic acids to high levels within the target cell. Such vectors utilize one of a number of powerful promoters to direct the high level of expression.
- Eukaryotic vectors use promoter-enhancer sequences of viral genes, especially those of tumor viruses.
- a particular embodiment of the invention provides for regulation of expression of the nucleic acid sequence encoding scatter factor using inducible promoters.
- inducible promoters include, but are not limited to, metallothionine promoters and mouse mammary tumor virus promoters.
- promoters and enhancers effective for use in the recombinant vectors include, but are not limited to, CMV (cytomegalovirus) , SV40 (simian virus 40) , HSV (herpes simplex virus) , EBV (epstein-barr virus) , retroviral, adenoviral promoters and enhancers, and tumor cell specific promoters and enhancers.
- CMV cytomegalovirus
- SV40 simian virus 40
- HSV herpes simplex virus
- EBV epstein-barr virus
- retroviral adenoviral promoters and enhancers
- tumor cell specific promoters and enhancers include, but are not limited to, CMV (cytomegalovirus) , SV40 (simian virus 40) , HSV (herpes simplex virus) , EBV (epstein-barr virus) , retroviral, adenoviral promoters and enhancers, and tumor cell specific promote
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002326053A CA2326053A1 (en) | 1998-03-26 | 1999-03-26 | Use of scatter factor to enhance angiogenesis |
AU32029/99A AU3202999A (en) | 1998-03-26 | 1999-03-26 | Use of scatter factor to enhance angiogenesis |
EP99914117A EP1066061A4 (en) | 1998-03-26 | 1999-03-26 | Use of scatter factor to enhance angiogenesis |
MXPA00009440A MXPA00009440A (en) | 1998-03-26 | 1999-03-26 | Use of scatter factor to enhance angiogenesis. |
JP2000537583A JP2002507584A (en) | 1998-03-26 | 1999-03-26 | Use of scattering factors to enhance angiogenesis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4881398A | 1998-03-26 | 1998-03-26 | |
US09/048,813 | 1998-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999048537A1 true WO1999048537A1 (en) | 1999-09-30 |
Family
ID=21956589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/006452 WO1999048537A1 (en) | 1998-03-26 | 1999-03-26 | Use of scatter factor to enhance angiogenesis |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1066061A4 (en) |
JP (1) | JP2002507584A (en) |
AU (1) | AU3202999A (en) |
CA (1) | CA2326053A1 (en) |
MX (1) | MXPA00009440A (en) |
WO (1) | WO1999048537A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1114862A2 (en) * | 1999-11-17 | 2001-07-11 | Switch Biotech Aktiengesellschaft | Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in indentifying pharmacologically acitve substances |
EP1391214A1 (en) * | 2001-05-09 | 2004-02-25 | Anges MG, Inc. | Gene transfer of angiogenic factor for skin disease |
EP1176200A3 (en) * | 2000-06-20 | 2005-01-12 | Switch Biotech Aktiengesellschaft | Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases or wound healing and their use in indentifying pharmacologically acitve substances |
WO2008020119A1 (en) * | 2006-08-16 | 2008-02-21 | Licentia Ltd. | Activated fibroblasts for treating tissue and/or organ damage |
US8609090B2 (en) | 2003-07-18 | 2013-12-17 | Amgen Inc. | Specific binding agents to hepatocyte growth factor |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652225A (en) * | 1994-10-04 | 1997-07-29 | St. Elizabeth's Medical Center Of Boston, Inc. | Methods and products for nucleic acid delivery |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248722B1 (en) * | 1995-08-29 | 2001-06-19 | Sumitomo Pharmaceuticals Company, Limited | Medicament comprising HGF gene |
WO1997012629A1 (en) * | 1995-10-05 | 1997-04-10 | Genentech, Inc. | Improved angiogenesis using hepatocyte growth factor |
-
1999
- 1999-03-26 MX MXPA00009440A patent/MXPA00009440A/en unknown
- 1999-03-26 CA CA002326053A patent/CA2326053A1/en not_active Abandoned
- 1999-03-26 WO PCT/US1999/006452 patent/WO1999048537A1/en not_active Application Discontinuation
- 1999-03-26 AU AU32029/99A patent/AU3202999A/en not_active Abandoned
- 1999-03-26 EP EP99914117A patent/EP1066061A4/en not_active Withdrawn
- 1999-03-26 JP JP2000537583A patent/JP2002507584A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652225A (en) * | 1994-10-04 | 1997-07-29 | St. Elizabeth's Medical Center Of Boston, Inc. | Methods and products for nucleic acid delivery |
Non-Patent Citations (3)
Title |
---|
ORKIN S H, MOTULSKY A G: "REPORT AND RECOMMENDATIONS OF THE PANEL TO ASSESS THE NIH INVESTMENT IN RESEARCH ON GENE THERAPY", REPORT AND RECOMMENDATIONS OF THE PANEL TO ACCESS THE NIHINVESTMENT IN RESEARCH ON GENE THERAPY, XX, XX, 7 December 1995 (1995-12-07), XX, pages 01 - 41, XP002918854 * |
See also references of EP1066061A4 * |
VERMA et al., "Gene Therapy - Promises, Problems and Prospects", SCIENCE, 18 September 1997, Vol. 389, pages 239-242, XP002918855 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1114862A2 (en) * | 1999-11-17 | 2001-07-11 | Switch Biotech Aktiengesellschaft | Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in indentifying pharmacologically acitve substances |
EP1114862A3 (en) * | 1999-11-17 | 2003-08-06 | Switch Biotech Aktiengesellschaft | Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in indentifying pharmacologically acitve substances |
EP1176200A3 (en) * | 2000-06-20 | 2005-01-12 | Switch Biotech Aktiengesellschaft | Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases or wound healing and their use in indentifying pharmacologically acitve substances |
EP1391214A1 (en) * | 2001-05-09 | 2004-02-25 | Anges MG, Inc. | Gene transfer of angiogenic factor for skin disease |
EP1391214A4 (en) * | 2001-05-09 | 2006-05-17 | Anges Mg Inc | Gene transfer of angiogenic factor for skin disease |
US7939504B2 (en) | 2001-05-09 | 2011-05-10 | Anges Mg, Inc. | Method of treating skin ulcers with vectors encoding hepatocyte growth factor |
US8609090B2 (en) | 2003-07-18 | 2013-12-17 | Amgen Inc. | Specific binding agents to hepatocyte growth factor |
WO2008020119A1 (en) * | 2006-08-16 | 2008-02-21 | Licentia Ltd. | Activated fibroblasts for treating tissue and/or organ damage |
Also Published As
Publication number | Publication date |
---|---|
JP2002507584A (en) | 2002-03-12 |
CA2326053A1 (en) | 1999-09-30 |
MXPA00009440A (en) | 2003-04-22 |
EP1066061A1 (en) | 2001-01-10 |
AU3202999A (en) | 1999-10-18 |
EP1066061A4 (en) | 2003-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6479654B1 (en) | Forms of the angiogenic factor vascular endothelial cell growth factor: VEGF | |
Takeshita et al. | Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia | |
US6685934B1 (en) | Recombinant adenoviruses coding for basic fibroblast growth factors (BFGF) | |
EP2162534A1 (en) | Cd34 stem cell-related methods and compositions | |
US6329348B1 (en) | Method of inducing angiogenesis | |
JP3877148B2 (en) | Gene therapy for diabetic ischemic disease | |
US7524493B2 (en) | Nucleic acid constructs cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension | |
EA005157B1 (en) | Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes | |
US7709450B2 (en) | Stimulation of vascularization with VEGF-B-186 | |
EP1066061A1 (en) | Use of scatter factor to enhance angiogenesis | |
US20030228283A1 (en) | Preventing secondary lymphedema with VEGF-D DNA | |
US6743623B2 (en) | Viral recombinant vectors for expression in muscle cells | |
US20030165464A1 (en) | In vivo stimulation of angiogenic activity | |
Webster | Therapeutic angiogenesis: a case for targeted, regulated gene delivery | |
US6099831A (en) | Viral recombinant vectors for expression in muscle cells | |
US20030148952A1 (en) | Methods and materials for the recruitment of endothelial cells | |
US7476654B2 (en) | Method for modulating, regulating and/or stabilizing angiogenesis | |
Vranckx et al. | 15 Gene Transfer of Growth Factors for Wound Repair | |
AU2002326311A1 (en) | Stimulation of vascularization with VEGF-B | |
AU2004200697A1 (en) | Variants of the Angiogenic Factor Vascular Endothelial Cell Growth Factor: VEGF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2326053 Country of ref document: CA Ref country code: CA Ref document number: 2326053 Kind code of ref document: A Format of ref document f/p: F Ref country code: JP Ref document number: 2000 537583 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/009440 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 32029/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999914117 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999914117 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999914117 Country of ref document: EP |